Objectives: Benzodiazepine use may be associated with delirium in critically ill children. However, benzodiazepines remain the first-line sedative choice in PICUs. Objectives were to determine the temporal relationship between administration of benzodiazepines and delirium development, control for time-varying covariates such as mechanical ventilation and opiates, and evaluate the association between dosage of benzodiazepines and subsequent delirium. Design: Retrospective observational study. Setting: Academic tertiary care PICU. Patients: All consecutive admissions from January 2015 to June 2015. Interventions: Retrospective assessment of benzodiazepine exposure in a population that had been prospectively screened for delirium. Measurements and Main Results: All subjects were prospectively screened for delirium throughout their stay, using the Cornell Assessment for Pediatric Delirium, with daily cognitive status assigned as follows: delirium, coma, or normal. Multivariable mixed effects modeling determined predictors of delirium overall, followed by subgroup analysis to assess effect of benzodiazepines on subsequent development of delirium. Marginal structural modeling was used to create a pseudorandomized sample and control for time-dependent variables, obtaining an unbiased estimate of the relationship between benzodiazepines and next day delirium. The cumulative daily dosage of benzodiazepines was calculated to test for a dose-response relationship. Benzodiazepines were strongly associated with transition from normal cognitive status to delirium, more than quadrupling delirium rates (odds ratio, 4.4; CI, 1.7–11.1; p
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2jxa7g9
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Lack of standard definitions of primary and secondary (non)responders after RYGB and SG makes it impossible to compare the litera...
-
Objective We examined whether teleconsultation from ambulances to a physician at an emergency medical communication center (EMCC) would incr...
-
FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm https://www.mdedge.com/hematologynews/article/191723/rare-diseases/...
-
CMS extends the prior authorization program, through Dec. 1, 2019, to eight states and Washington DC from EMS via xlomafota13 on Inoreader...
-
Review of the pathology underlying benign paroxysmal positional vertigo Sertac Yetiser First Published December 29, 2019 Review Article Fi...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου